We are live on ! Find out more
TNYA icon

Tenaya Therapeutics

89 hedge funds and large institutions have $19.3M invested in Tenaya Therapeutics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more call options, than puts

Call options by funds: $137K | Put options by funds: $49K

9% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

12.14% less ownership

Funds ownership: 31.52%19.37% (-12%)

17% less funds holding

Funds holding: 10789 (-18)

30% less capital invested

Capital invested by funds: $27.7M → $19.3M (-$8.44M)

47% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 38

Holders
89
Holders Change
-18
Holders Change %
-16.82%
% of All Funds
1.17%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
20
Increased
25
Reduced
23
Closed
38
Calls
$137K
Puts
$49K
Net Calls
+$88K
Net Calls Change
+$16K
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
126
Sterling Capital Management
North Carolina
-$402 -705 Closed
RA
127
Rise Advisors
New York
-$276 -485 Closed

TNYA Hedge Fund Activity: Q2 2025 in Review

89 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Tenaya Therapeutics (TNYA) for Q2 2025, worth a combined $19.3M — down 30% from $27.7M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of TNYA and 20 opened new positions — a net loss of 18 holders — while 23 trimmed existing stakes and 25 added.

The largest buyer was AQR Capital Management, adding an estimated $492K. The largest seller was Woodline Partners, exiting entirely with an estimated $3.37M sold.

  • 89 institutional investors held Tenaya Therapeutics (TNYA) as of Q2 2025, down from 107 in Q1 2025.
  • Funds reported $19.3M of Tenaya Therapeutics stock for Q2 2025, down 30% quarter-over-quarter.
  • 20 funds opened new Tenaya Therapeutics positions in Q2 2025 and 38 closed out, a net change of -18 holders.
  • The largest Tenaya Therapeutics buyer in Q2 2025 was AQR Capital Management, an estimated $492K added.
  • The largest Tenaya Therapeutics seller in Q2 2025 was Woodline Partners, an estimated $3.37M sold.

Based on aggregated 13F filings for Q2 2025.